What is the efficacy and safety of enoxaparin compared with unfractionated heparin for high-risk patients with non-ST-segment elevation acute coronary syndrome?
The efficacy and safety of enoxaparin compared with unfractionated heparin for high-risk patients with non-ST-segment elevation acute coronary syndrome was studied in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. The results of the trial showed that enoxaparin was associated with a superior safety profile and efficacy in comparison to unfractionated heparin for the treatment of high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention.